Scryb -- ehemals Vervielfachungschance_ChroMedX (Seite 550)
eröffnet am 23.10.14 08:22:42 von
neuester Beitrag 16.04.24 22:02:52 von
neuester Beitrag 16.04.24 22:02:52 von
Beiträge: 12.069
ID: 1.201.093
ID: 1.201.093
Aufrufe heute: 437
Gesamt: 1.266.163
Gesamt: 1.266.163
Aktive User: 0
ISIN: CA81111V1076 · WKN: A3C86A
0,0200
EUR
0,00 %
0,0000 EUR
Letzter Kurs 22:33:04 Lang & Schwarz
Werte aus der Branche Informationstechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5400 | +191,89 | |
| 1,4000 | +30,84 | |
| 1,7000 | +30,77 | |
| 1,7500 | +30,60 | |
| 1,5200 | +26,66 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 17,400 | -14,71 | |
| 15,500 | -17,55 | |
| 0,5100 | -36,25 | |
| 7,0000 | -62,10 | |
| 12,300 | -73,38 |
Beitrag zu dieser Diskussion schreiben
Feedback
Hammergeil hier sehen wir wieder Kurse von 0,50 cents und bei der nächsten News mit Fionet Aufträge wieder die Hochs von letzter Woche 
Zockerbude auf Tradegate schon am Start 15% plus....🤭😉 .. läuft!!!!
Antwort auf Beitrag Nr.: 67.046.523 von TryVistor am 17.02.21 07:07:50Also, ich finde es in gewisser Hinsicht "bewundernswert", wenn in diesem Forum Menschen gibt, die Ihre wertvolle Zeit investieren, um einen "heiligen Schein" zu erwerben, indem sie,... selbstlos... und ...ohne Rücksicht auf Verluste, ...durch wilde Hypothesen, anderen helfen möchten.😌 Ich habe es immer gewusst, man sollte an das "Gute im Menschen glauben", insbesondere im Aktiengeschäft.
Relay's Glow, Swiss Pharmacan enter distribution deal
2021-02-16 16:50 ET - News Release
Mr. W. Clark Kent reports
RELAY MEDICAL REPORTS GLOW LIFETECH SECURES EXCLUSIVE NORTH AMERICAN RIGHTS TO ARTEMIC FOLLOWING SUCCESSFUL COVID-19 PHASE II CLINICAL TRIAL
Glow LifeTech Ltd., a private company in which Relay Medical Corp. holds a significant equity interest, has executed an agreement with Swiss Pharmacan AG for exclusive North American and Carribean sales and distribution rights for ArtemiC, a natural health product based on Glow's MyCell technology, which recently reported successful results from a COVID-19 phase 2 clinical trial (see Relay's release dated Jan. 14, 2021).
Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, U.S., Mexico and all Carribean countries as a food supplement. ArtemiC is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses Glow's MyCell delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC was a collaborative development effort with Glow's strategic partner, Swiss PharmaCan AG and MGC Pharma ("MGC"), and will be manufactured by MGC Pharma under EU-GMP.
"This is a significant new product opportunity for Glow and our shareholders, as ArtemiC shows promising results that it may improve the clinical recovery of COVID-19 patients," said Rob Carducci, Chief Commercial Officer, Glow LifeTech Ltd. "We are extremely pleased that our MyCell Technology is helping to power a natural, safe and effective product that can be made widely accessible during these challenging times."
Recently, MGC announced the results of a Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group[1]. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing done by MGC on toxicity and mechanism of action.
"We continue to be encouraged with the broad applications of MyCell delivery technology and Glow's commitment to bring scientifically-validated products to market," said Yoav Raiter, CEO, Relay Medical Corp. "We believe ArtemiC is just the first of many innovative products to come from Glow, and as such, Relay has committed to participating in their recent RTO financing."
On February 9, 2021, Relay announced its participation in the go-public financing of Glow, investing an additional $600,000 to minimize dilution of its equity position. The Glow go-public financing was oversubscribed for a total of $4,640,000 which is part of its conditional approval to list its common shares on the CSE.
Glow and Swiss PharmaCan are now preparing regulatory submissions to pave the way for North American commercialization as a food supplement, or equivalent, in each of the relevant jurisdictions.
About Relay Medical Corp.
Relay Medical is a technology developer and innovator headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.
http://www.stockwatch.com/News/Item?bid=Z-C:RELA-3032594&sym…
2021-02-16 16:50 ET - News Release
Mr. W. Clark Kent reports
RELAY MEDICAL REPORTS GLOW LIFETECH SECURES EXCLUSIVE NORTH AMERICAN RIGHTS TO ARTEMIC FOLLOWING SUCCESSFUL COVID-19 PHASE II CLINICAL TRIAL
Glow LifeTech Ltd., a private company in which Relay Medical Corp. holds a significant equity interest, has executed an agreement with Swiss Pharmacan AG for exclusive North American and Carribean sales and distribution rights for ArtemiC, a natural health product based on Glow's MyCell technology, which recently reported successful results from a COVID-19 phase 2 clinical trial (see Relay's release dated Jan. 14, 2021).
Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC in Canada, U.S., Mexico and all Carribean countries as a food supplement. ArtemiC is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses Glow's MyCell delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC was a collaborative development effort with Glow's strategic partner, Swiss PharmaCan AG and MGC Pharma ("MGC"), and will be manufactured by MGC Pharma under EU-GMP.
"This is a significant new product opportunity for Glow and our shareholders, as ArtemiC shows promising results that it may improve the clinical recovery of COVID-19 patients," said Rob Carducci, Chief Commercial Officer, Glow LifeTech Ltd. "We are extremely pleased that our MyCell Technology is helping to power a natural, safe and effective product that can be made widely accessible during these challenging times."
Recently, MGC announced the results of a Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group[1]. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing done by MGC on toxicity and mechanism of action.
"We continue to be encouraged with the broad applications of MyCell delivery technology and Glow's commitment to bring scientifically-validated products to market," said Yoav Raiter, CEO, Relay Medical Corp. "We believe ArtemiC is just the first of many innovative products to come from Glow, and as such, Relay has committed to participating in their recent RTO financing."
On February 9, 2021, Relay announced its participation in the go-public financing of Glow, investing an additional $600,000 to minimize dilution of its equity position. The Glow go-public financing was oversubscribed for a total of $4,640,000 which is part of its conditional approval to list its common shares on the CSE.
Glow and Swiss PharmaCan are now preparing regulatory submissions to pave the way for North American commercialization as a food supplement, or equivalent, in each of the relevant jurisdictions.
About Relay Medical Corp.
Relay Medical is a technology developer and innovator headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.
http://www.stockwatch.com/News/Item?bid=Z-C:RELA-3032594&sym…
Antwort auf Beitrag Nr.: 67.046.523 von TryVistor am 17.02.21 07:07:50Und jetzt redet ganz Deutschland von Schnelltests.
Ich hätte jetzt ohne nachzuschauen nicht einen Herstellernamen parat.
Und trotzdem kommen sie in Mengen.
Ich hätte jetzt ohne nachzuschauen nicht einen Herstellernamen parat.
Und trotzdem kommen sie in Mengen.
Trading Spotlight
Antwort auf Beitrag Nr.: 67.045.524 von ahnungslos80 am 16.02.21 23:22:27Nicht Tschüss sondern guten Tag, wer verschwinden wird, seid ihr und eure billige Werbung für eine Abzockerbude. Der angebliche 100%ige Heilmittel ist nur eine billige Werbung, die glaubt kein vernünftiger Mensch. Wenn sie wahr wär, wäre schon in den Medien gekommen.
Über BioNtech sprach die ganze Welt fast ein Jahr bevor der Implfstoff raus war.
Über BioNtech sprach die ganze Welt fast ein Jahr bevor der Implfstoff raus war.
Antwort auf Beitrag Nr.: 67.045.983 von ceovonnichts am 17.02.21 01:01:01
Ich muss gestehen, ich hatte anfangs meine Probleme mit ihm als der Kurs bei EUR 0,13 stand und er hier zu ‚warnen‘ begann..
Aber inzwischen muss ich beipflichten, fugazi und der nach ihm benannte Chart Effekt sind schon eine Bank was Kurssteigerungen angeht! 👍
Schade dass ihr nur hier rumlungert, ich würde glatt ohne viel Recherche alle Papiere kaufen, vor denen ihr Angst habt! 👍😂
Zitat von ceovonnichts: Dieser Fugazi einfach genial.
Ich muss gestehen, ich hatte anfangs meine Probleme mit ihm als der Kurs bei EUR 0,13 stand und er hier zu ‚warnen‘ begann..
Aber inzwischen muss ich beipflichten, fugazi und der nach ihm benannte Chart Effekt sind schon eine Bank was Kurssteigerungen angeht! 👍
Schade dass ihr nur hier rumlungert, ich würde glatt ohne viel Recherche alle Papiere kaufen, vor denen ihr Angst habt! 👍😂
Schön, dass noch andere bemerken, was für ein falsches Spiel gespielt wird.
Aber eigentlich sieht der Chart mit den beiden gewaltigen Peaks und dazwischen nichts, schon allein nach Abzocke aus. Meiner Meinung nach zumindesT:
Aber eigentlich sieht der Chart mit den beiden gewaltigen Peaks und dazwischen nichts, schon allein nach Abzocke aus. Meiner Meinung nach zumindesT:
Einfaches Einfügen von wallstreetONLINE Charts: So funktionierts.
Wie von Fugazi schon richtig analysiert, werden von den üblichen Verdächtigen spätabends noch positive Beiträge erstellt. Richtig schön, da können die sich mal wieder die Bälle gegenseitig zuspielen.
Dieser Fugazi einfach genial.
Dieser Fugazi einfach genial.
Antwort auf Beitrag Nr.: 67.045.716 von ahnungslos80 am 16.02.21 23:47:20Ich darf schätzen?
Wir jonglieren hier mit 9- bis 11-stelligen Zahlen, also mit einem Multiplikator ab 40x aufwärts.
Wir jonglieren hier mit 9- bis 11-stelligen Zahlen, also mit einem Multiplikator ab 40x aufwärts.
Durchsuchen
Scryb -- ehemals Vervielfachungschance_ChroMedX
